Nerve regeneration promoters containing semaphorin inhibitor as the active ingredient

• US 7,317,038 B2
• Filed: 08/24/2006
• Issued: 01/08/2008
• Est. Priority Date: 07/28/2000
• Status: Expired due to Fees

• Current Assignee: Dainippon Sumitomo Pharma Company Limited (Sumitomo Chemical Company Limited)
• Original Assignee: Dainippon Sumitomo Pharma Company Limited (Sumitomo Chemical Company Limited)
• Inventors: Kimura, Toru, Kishino, Akiyoshi, Kikuchi, Kaoru, Hosotani, Nobuo, Kumagai, Kazuo
• Primary Examiner(s): Anderson; Rebecca
• Assistant Examiner(s): CHUNG, SUSANNAH LEE
• Application Number:
  US11/508,965
• Publication Number:
  US 20070015820A1
• Time in Patent Office: 502 Days
• Field of Search: 514/455, 435/17, 549/391, 549/413
• US Class Current: 514/455
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 311/78 Ring systems having three or more relevant rings
• CPC Class Codes: C07D 311/86 Oxygen atoms, e.g. xanthones
• CPC Class Codes: C07D 493/04 Ortho-condensed systems

Abstract

To provide a semaphorin inhibitor; a peripheral or central nerve regeneration promoter which contains said semaphorin inhibitor as an active ingredient; and a preventive or remedy for a neuropathic disease and a neurodegenerative disease containing said nerve regeneration promoter, or the like.

A low-molecular weight compound, which acts at a concentration of 10 μg/ml or below to inhibit the growth cone collapse activity of semaphorin such as semaphorin 3A, semaphorin 6C or the like and/or the nerve outgrowth inhibitory activity of semaphorin in a collagen gel and which does not substantially affect cell proliferation, is obtained from the culture of strain SPF-3059 belonging to the genus Penicillium. The low-molecular weight compound with the semaphorin inhibitory activity thus obtained exhibits the in vivo nerve-regeneration promoting action.

Claims

1. A compound represented by formula [13], or a pharmaceutically acceptable salt thereof,

2. The compound according to claim 1 wherein at least one of R² and R⁵ represents a hydroxyl group, or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 2 wherein R² represents a hydroxyl group, or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 2 wherein R² and R⁵ represent a hydroxyl group, or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1 wherein R⁴ represents a carboxyl group, or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1 wherein R² represents a hydroxyl group and R⁴ represents a carboxyl group, or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 1 wherein R¹ and R⁴ represent a carboxyl group and R⁵ represents a hydroxyl group, or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 2 wherein R⁴ represents a carboxyl group or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 3 wherein R⁴ represents a carboxyl group or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 4 wherein R⁴ represents a carboxyl group or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition for nerve regeneration comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

12. A method for stimulating nerve regeneration, comprising administering an effective amount of the compound of claim 1 to an individual in need thereof.